Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 75 entries
Sorted by: Best Match Show Resources per page
Clinical Characteristics, Surgical Management and Adjuvant Therapy of Patients with Uterine Carcinosarcoma: A Retrospective Case Series.

Geburtshilfe und Frauenheilkunde

Wallwiener C, Hartkopf A, Kommoss S, Joachim C, Wallwiener M, Taran FA, Brucker S.
PMID: 26941453
Geburtshilfe Frauenheilkd. 2016 Feb;76(2):188-193. doi: 10.1055/s-0042-100205.

No abstract available.

Cite
Wallwiener C, Hartkopf A, Kommoss S, et al. Clinical Characteristics, Surgical Management and Adjuvant Therapy of Patients with Uterine Carcinosarcoma: A Retrospective Case Series. Geburtshilfe Frauenheilkd. 2016;76(2):188-193doi: 10.1055/s-0042-100205.
Wallwiener, C., Hartkopf, A., Kommoss, S., Joachim, C., Wallwiener, M., Taran, F. A., & Brucker, S. (2016). Clinical Characteristics, Surgical Management and Adjuvant Therapy of Patients with Uterine Carcinosarcoma: A Retrospective Case Series. Geburtshilfe und Frauenheilkunde, 76(2), 188-193. https://doi.org/10.1055/s-0042-100205
Wallwiener, C, et al. "Clinical Characteristics, Surgical Management and Adjuvant Therapy of Patients with Uterine Carcinosarcoma: A Retrospective Case Series." Geburtshilfe und Frauenheilkunde vol. 76,2 (2016): 188-193. doi: https://doi.org/10.1055/s-0042-100205
Wallwiener C, Hartkopf A, Kommoss S, Joachim C, Wallwiener M, Taran FA, Brucker S. Clinical Characteristics, Surgical Management and Adjuvant Therapy of Patients with Uterine Carcinosarcoma: A Retrospective Case Series. Geburtshilfe Frauenheilkd. 2016 Feb;76(2):188-193. doi: 10.1055/s-0042-100205. PMID: 26941453; PMCID: PMC4771506.
Copy Download .nbib Format: NLM
Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention.

Geburtshilfe und Frauenheilkunde

Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wallwiener D, Brucker SY, Schütz F, Fasching PA, Fehm TN.
PMID: 29576630
Geburtshilfe Frauenheilkd. 2018 Mar;78(3):246-259. doi: 10.1055/s-0044-101614. Epub 2018 Mar 21.

The treatment of metastatic breast cancer has become more complicated due to increasing numbers of new therapies which need to be tested. Therapies are now being developed to treat special clinical or molecular subgroups. Even though intrinsic molecular subtypes...

Cite
Schneeweiss A, Lux MP, Janni W, et al. Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe Frauenheilkd. 2018;78(3):246-259doi: 10.1055/s-0044-101614.
Schneeweiss, A., Lux, M. P., Janni, W., Hartkopf, A. D., Nabieva, N., Taran, F. A., Overkamp, F., Kolberg, H. C., Hadji, P., Tesch, H., Wöckel, A., Ettl, J., Lüftner, D., Wallwiener, M., Müller, V., Beckmann, M. W., Belleville, E., Wallwiener, D., Brucker, S. Y., Schütz, F., Fasching, P. A., & Fehm, T. N. (2018). Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe und Frauenheilkunde, 78(3), 246-259. https://doi.org/10.1055/s-0044-101614
Schneeweiss, Andreas, et al. "Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention." Geburtshilfe und Frauenheilkunde vol. 78,3 (2018): 246-259. doi: https://doi.org/10.1055/s-0044-101614
Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wallwiener D, Brucker SY, Schütz F, Fasching PA, Fehm TN. Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe Frauenheilkd. 2018 Mar;78(3):246-259. doi: 10.1055/s-0044-101614. Epub 2018 Mar 21. PMID: 29576630; PMCID: PMC5862553.
Copy Download .nbib Format: NLM
Willingness of Patients with Breast Cancer in the Adjuvant and Metastatic Setting to Use Electronic Surveys (ePRO) Depends on Sociodemographic Factors, Health-related Quality of Life, Disease Status and Computer Skills.

Geburtshilfe und Frauenheilkunde

Graf J, Simoes E, Wißlicen K, Rava L, Walter CB, Hartkopf A, Keilmann L, Taran A, Wallwiener S, Fasching P, Brucker SY, Wallwiener M.
PMID: 27239062
Geburtshilfe Frauenheilkd. 2016 May;76(5):535-541. doi: 10.1055/s-0042-105872.

No abstract available.

Cite
Graf J, Simoes E, Wißlicen K, et al. Willingness of Patients with Breast Cancer in the Adjuvant and Metastatic Setting to Use Electronic Surveys (ePRO) Depends on Sociodemographic Factors, Health-related Quality of Life, Disease Status and Computer Skills. Geburtshilfe Frauenheilkd. 2016;76(5):535-541doi: 10.1055/s-0042-105872.
Graf, J., Simoes, E., Wißlicen, K., Rava, L., Walter, C. B., Hartkopf, A., Keilmann, L., Taran, A., Wallwiener, S., Fasching, P., Brucker, S. Y., & Wallwiener, M. (2016). Willingness of Patients with Breast Cancer in the Adjuvant and Metastatic Setting to Use Electronic Surveys (ePRO) Depends on Sociodemographic Factors, Health-related Quality of Life, Disease Status and Computer Skills. Geburtshilfe und Frauenheilkunde, 76(5), 535-541. https://doi.org/10.1055/s-0042-105872
Graf, J, et al. "Willingness of Patients with Breast Cancer in the Adjuvant and Metastatic Setting to Use Electronic Surveys (ePRO) Depends on Sociodemographic Factors, Health-related Quality of Life, Disease Status and Computer Skills." Geburtshilfe und Frauenheilkunde vol. 76,5 (2016): 535-541. doi: https://doi.org/10.1055/s-0042-105872
Graf J, Simoes E, Wißlicen K, Rava L, Walter CB, Hartkopf A, Keilmann L, Taran A, Wallwiener S, Fasching P, Brucker SY, Wallwiener M. Willingness of Patients with Breast Cancer in the Adjuvant and Metastatic Setting to Use Electronic Surveys (ePRO) Depends on Sociodemographic Factors, Health-related Quality of Life, Disease Status and Computer Skills. Geburtshilfe Frauenheilkd. 2016 May;76(5):535-541. doi: 10.1055/s-0042-105872. PMID: 27239062; PMCID: PMC4873300.
Copy Download .nbib Format: NLM
ASCO 2019: New Results in Breast Cancer.

Breast care (Basel, Switzerland)

Gluz O, Hartkopf A, Kümmel S, Marmé F.
PMID: 31558899
Breast Care (Basel). 2019 Aug;14(4):256-258. doi: 10.1159/000501874. Epub 2019 Aug 06.

No abstract available.

Cite
Gluz O, Hartkopf A, Kümmel S, et al. ASCO 2019: New Results in Breast Cancer. Breast Care (Basel). 2019;14(4):256-258doi: 10.1159/000501874.
Gluz, O., Hartkopf, A., Kümmel, S., & Marmé, F. (2019). ASCO 2019: New Results in Breast Cancer. Breast care (Basel, Switzerland), 14(4), 256-258. https://doi.org/10.1159/000501874
Gluz, Oleg, et al. "ASCO 2019: New Results in Breast Cancer." Breast care (Basel, Switzerland) vol. 14,4 (2019): 256-258. doi: https://doi.org/10.1159/000501874
Gluz O, Hartkopf A, Kümmel S, Marmé F. ASCO 2019: New Results in Breast Cancer. Breast Care (Basel). 2019 Aug;14(4):256-258. doi: 10.1159/000501874. Epub 2019 Aug 06. PMID: 31558899; PMCID: PMC6751419.
Copy Download .nbib Format: NLM
gNOMO: a multi-omics pipeline for integrated host and microbiome analysis of non-model organisms.

NAR genomics and bioinformatics

Muñoz-Benavent M, Hartkopf F, Van Den Bossche T, Piro VC, García-Ferris C, Latorre A, Renard BY, Muth T.
PMID: 33575609
NAR Genom Bioinform. 2020 Aug 05;2(3):lqaa058. doi: 10.1093/nargab/lqaa058. eCollection 2020 Sep.

The study of bacterial symbioses has grown exponentially in the recent past. However, existing bioinformatic workflows of microbiome data analysis do commonly not integrate multiple meta-omics levels and are mainly geared toward human microbiomes. Microbiota are better understood when...

Cite
Muñoz-Benavent M, Hartkopf F, Van Den Bossche T, et al. gNOMO: a multi-omics pipeline for integrated host and microbiome analysis of non-model organisms. NAR Genom Bioinform. 2020;2(3):lqaa058doi: 10.1093/nargab/lqaa058.
Muñoz-Benavent, M., Hartkopf, F., Van Den Bossche, T., Piro, V. C., García-Ferris, C., Latorre, A., Renard, B. Y., & Muth, T. (2020). gNOMO: a multi-omics pipeline for integrated host and microbiome analysis of non-model organisms. NAR genomics and bioinformatics, 2(3), lqaa058. https://doi.org/10.1093/nargab/lqaa058
Muñoz-Benavent, Maria, et al. "gNOMO: a multi-omics pipeline for integrated host and microbiome analysis of non-model organisms." NAR genomics and bioinformatics vol. 2,3 (2020): lqaa058. doi: https://doi.org/10.1093/nargab/lqaa058
Muñoz-Benavent M, Hartkopf F, Van Den Bossche T, Piro VC, García-Ferris C, Latorre A, Renard BY, Muth T. gNOMO: a multi-omics pipeline for integrated host and microbiome analysis of non-model organisms. NAR Genom Bioinform. 2020 Aug 05;2(3):lqaa058. doi: 10.1093/nargab/lqaa058. eCollection 2020 Sep. PMID: 33575609; PMCID: PMC7671378.
Copy Download .nbib Format: NLM
Update Breast Cancer 2021 Part 3 - Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel.

Geburtshilfe und Frauenheilkunde

Fehm TN, Stickeler E, Fasching PA, Janni W, Kolberg-Liedtke C, Kolberg HC, Lüftner D, Müller V, Schütz F, Thomssen C, Belleville E, Behrens A, Bader S, Untch M, Welslau M, Würstlein R, Thill M, Krug D, Hartkopf AD.
PMID: 34168379
Geburtshilfe Frauenheilkd. 2021 Jun;81(6):654-665. doi: 10.1055/a-1487-7642. Epub 2021 Jun 21.

The continuous availability of findings from new studies repeatedly results in updated treatment recommendations and guidelines. In the case of breast carcinoma in particular, several studies have been published in the last few years that have transformed how early...

Cite
Fehm TN, Stickeler E, Fasching PA, et al. Update Breast Cancer 2021 Part 3 - Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. Geburtshilfe Frauenheilkd. 2021;81(6):654-665doi: 10.1055/a-1487-7642.
Fehm, T. N., Stickeler, E., Fasching, P. A., Janni, W., Kolberg-Liedtke, C., Kolberg, H. C., Lüftner, D., Müller, V., Schütz, F., Thomssen, C., Belleville, E., Behrens, A., Bader, S., Untch, M., Welslau, M., Würstlein, R., Thill, M., Krug, D., & Hartkopf, A. D. (2021). Update Breast Cancer 2021 Part 3 - Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. Geburtshilfe und Frauenheilkunde, 81(6), 654-665. https://doi.org/10.1055/a-1487-7642
Fehm, Tanja N, et al. "Update Breast Cancer 2021 Part 3 - Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel." Geburtshilfe und Frauenheilkunde vol. 81,6 (2021): 654-665. doi: https://doi.org/10.1055/a-1487-7642
Fehm TN, Stickeler E, Fasching PA, Janni W, Kolberg-Liedtke C, Kolberg HC, Lüftner D, Müller V, Schütz F, Thomssen C, Belleville E, Behrens A, Bader S, Untch M, Welslau M, Würstlein R, Thill M, Krug D, Hartkopf AD. Update Breast Cancer 2021 Part 3 - Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. Geburtshilfe Frauenheilkd. 2021 Jun;81(6):654-665. doi: 10.1055/a-1487-7642. Epub 2021 Jun 21. PMID: 34168379; PMCID: PMC8216783.
Copy Download .nbib Format: NLM
Regulation of Platelet-Derived ADAM17: A Biomarker Approach for Breast Cancer?.

Diagnostics (Basel, Switzerland)

Zhou Y, Heitmann JS, Kropp KN, Hinterleitner M, Koch A, Hartkopf AD, Salih HR, Hinterleitner C, Maurer S.
PMID: 34208863
Diagnostics (Basel). 2021 Jun 30;11(7). doi: 10.3390/diagnostics11071188.

Tumor progression and metastasis are critically dependent on the tumor microenvironment. A disintegrin and metalloproteinase 17 (ADAM17) is associated with shedding of several substrates involved in tumor progression and known to be expressed by platelets of healthy donors and...

Cite
Zhou Y, Heitmann JS, Kropp KN, et al. Regulation of Platelet-Derived ADAM17: A Biomarker Approach for Breast Cancer?. Diagnostics (Basel). 2021;11(7)doi: 10.3390/diagnostics11071188.
Zhou, Y., Heitmann, J. S., Kropp, K. N., Hinterleitner, M., Koch, A., Hartkopf, A. D., Salih, H. R., Hinterleitner, C., & Maurer, S. (2021). Regulation of Platelet-Derived ADAM17: A Biomarker Approach for Breast Cancer?. Diagnostics (Basel, Switzerland), 11(7), . https://doi.org/10.3390/diagnostics11071188
Zhou, Yanjun, et al. "Regulation of Platelet-Derived ADAM17: A Biomarker Approach for Breast Cancer?." Diagnostics (Basel, Switzerland) vol. 11,7 (2021). doi: https://doi.org/10.3390/diagnostics11071188
Zhou Y, Heitmann JS, Kropp KN, Hinterleitner M, Koch A, Hartkopf AD, Salih HR, Hinterleitner C, Maurer S. Regulation of Platelet-Derived ADAM17: A Biomarker Approach for Breast Cancer?. Diagnostics (Basel). 2021 Jun 30;11(7). doi: 10.3390/diagnostics11071188. PMID: 34208863; PMCID: PMC8305148.
Copy Download .nbib Format: NLM
Large Conization-Retrospective Monocentric Results for Fertility Preservation in Young Women with Early Stage Cervical Cancer.

Reproductive sciences (Thousand Oaks, Calif.)

Tsaousidis C, Kraemer B, Kommoss S, Hartkopf A, Brucker S, Neis K, Andress J, Neis F.
PMID: 34845668
Reprod Sci. 2021 Nov 29; doi: 10.1007/s43032-021-00807-9. Epub 2021 Nov 29.

The shorter cervical segment after classic radical trachelectomy (RT) imposes a number of pregnancy associated risk factors. In this aspect, large conization (LC) could be an oncologically safe alternative to RT in young women with early stage cervical cancer...

Cite
Tsaousidis C, Kraemer B, Kommoss S, et al. Large Conization-Retrospective Monocentric Results for Fertility Preservation in Young Women with Early Stage Cervical Cancer. Reprod Sci. 2021;doi: 10.1007/s43032-021-00807-9.
Tsaousidis, C., Kraemer, B., Kommoss, S., Hartkopf, A., Brucker, S., Neis, K., Andress, J., & Neis, F. (2021). Large Conization-Retrospective Monocentric Results for Fertility Preservation in Young Women with Early Stage Cervical Cancer. Reproductive sciences (Thousand Oaks, Calif.), . https://doi.org/10.1007/s43032-021-00807-9
Tsaousidis, Christos, et al. "Large Conization-Retrospective Monocentric Results for Fertility Preservation in Young Women with Early Stage Cervical Cancer." Reproductive sciences (Thousand Oaks, Calif.) vol. (2021). doi: https://doi.org/10.1007/s43032-021-00807-9
Tsaousidis C, Kraemer B, Kommoss S, Hartkopf A, Brucker S, Neis K, Andress J, Neis F. Large Conization-Retrospective Monocentric Results for Fertility Preservation in Young Women with Early Stage Cervical Cancer. Reprod Sci. 2021 Nov 29; doi: 10.1007/s43032-021-00807-9. Epub 2021 Nov 29. PMID: 34845668.
Copy Download .nbib Format: NLM
Isling: a tool for detecting integration of wild-type viruses and clinical vectors.

Journal of molecular biology

Scott S, Hallwirth CV, Hartkopf F, Grigson S, Jain Y, Alexander IE, Bauer DC, O W Wilson L.
PMID: 34929203
J Mol Biol. 2021 Dec 17;167408. doi: 10.1016/j.jmb.2021.167408. Epub 2021 Dec 17.

Detecting viral and vector integration events is a key step when investigating interactions between viral and host genomes. This is relevant in several fields, including virology, cancer research and gene therapy. For example, investigating integrations of wild-type viruses such...

Cite
Scott S, Hallwirth CV, Hartkopf F, et al. Isling: a tool for detecting integration of wild-type viruses and clinical vectors. J Mol Biol. 2021;167408doi: 10.1016/j.jmb.2021.167408.
Scott, S., Hallwirth, C. V., Hartkopf, F., Grigson, S., Jain, Y., Alexander, I. E., Bauer, D. C., & O W Wilson, L. (2021). Isling: a tool for detecting integration of wild-type viruses and clinical vectors. Journal of molecular biology, 167408. https://doi.org/10.1016/j.jmb.2021.167408
Scott, Suzanne, et al. "Isling: a tool for detecting integration of wild-type viruses and clinical vectors." Journal of molecular biology vol. (2021): 167408. doi: https://doi.org/10.1016/j.jmb.2021.167408
Scott S, Hallwirth CV, Hartkopf F, Grigson S, Jain Y, Alexander IE, Bauer DC, O W Wilson L. Isling: a tool for detecting integration of wild-type viruses and clinical vectors. J Mol Biol. 2021 Dec 17;167408. doi: 10.1016/j.jmb.2021.167408. Epub 2021 Dec 17. PMID: 34929203.
Copy Download .nbib Format: NLM
Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics.

Geburtshilfe und Frauenheilkunde

Lüftner D, Schneeweiss A, Hartkopf AD, Müller V, Wöckel A, Janni W, Ettl J, Belleville E, Schütz F, Thill M, Huober J, Fasching PA, Kolberg HC, Pöschke P, Welslau M, Overkamp F, Tesch H, Fehm TN, Lux MP.
PMID: 32322108
Geburtshilfe Frauenheilkd. 2020 Apr;80(4):391-398. doi: 10.1055/a-1111-8775. Epub 2020 Apr 21.

For patients with locally advanced or metastatic breast cancer, new and effective therapies such as CDK4/6 inhibitors, PARP inhibitors and a PD-L1 inhibitor have been introduced in recent years. This review presents an update on the available studies with...

Cite
Lüftner D, Schneeweiss A, Hartkopf AD, et al. Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. Geburtshilfe Frauenheilkd. 2020;80(4):391-398doi: 10.1055/a-1111-8775.
Lüftner, D., Schneeweiss, A., Hartkopf, A. D., Müller, V., Wöckel, A., Janni, W., Ettl, J., Belleville, E., Schütz, F., Thill, M., Huober, J., Fasching, P. A., Kolberg, H. C., Pöschke, P., Welslau, M., Overkamp, F., Tesch, H., Fehm, T. N., & Lux, M. P. (2020). Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. Geburtshilfe und Frauenheilkunde, 80(4), 391-398. https://doi.org/10.1055/a-1111-8775
Lüftner, Diana, et al. "Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics." Geburtshilfe und Frauenheilkunde vol. 80,4 (2020): 391-398. doi: https://doi.org/10.1055/a-1111-8775
Lüftner D, Schneeweiss A, Hartkopf AD, Müller V, Wöckel A, Janni W, Ettl J, Belleville E, Schütz F, Thill M, Huober J, Fasching PA, Kolberg HC, Pöschke P, Welslau M, Overkamp F, Tesch H, Fehm TN, Lux MP. Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. Geburtshilfe Frauenheilkd. 2020 Apr;80(4):391-398. doi: 10.1055/a-1111-8775. Epub 2020 Apr 21. PMID: 32322108; PMCID: PMC7174003.
Copy Download .nbib Format: NLM
Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status.

European journal of cancer (Oxford, England : 1990)

Hein A, Hartkopf AD, Emons J, Lux MP, Volz B, Taran FA, Overkamp F, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wurmthaler LA, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Kurbacher CM, Wuerstlein R, Thomssen C, Untch M, Fasching PA, Janni W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Kolberg HC.
PMID: 34311211
Eur J Cancer. 2021 Sep;155:1-12. doi: 10.1016/j.ejca.2021.06.033. Epub 2021 Jul 23.

PURPOSE: Assessment of HER2 overexpression using immunohistochemistry (IHC) and/or in situ hybridisation (ISH) for the detection of HER2 amplifications is standard to identify patients for established HER2-directed treatments. Patients with lower HER2 expression levels have recently also become candidates...

Cite
Hein A, Hartkopf AD, Emons J, et al. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. Eur J Cancer. 2021;155:1-12doi: 10.1016/j.ejca.2021.06.033.
Hein, A., Hartkopf, A. D., Emons, J., Lux, M. P., Volz, B., Taran, F. A., Overkamp, F., Hadji, P., Tesch, H., Häberle, L., Ettl, J., Lüftner, D., Wurmthaler, L. A., Wallwiener, M., Müller, V., Beckmann, M. W., Belleville, E., Wimberger, P., Hielscher, C., Kurbacher, C. M., Wuerstlein, R., Thomssen, C., Untch, M., Fasching, P. A., Janni, W., Fehm, T. N., Wallwiener, D., Brucker, S. Y., Schneeweiss, A., & Kolberg, H. C. (2021). Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. European journal of cancer (Oxford, England : 1990), 1551-12. https://doi.org/10.1016/j.ejca.2021.06.033
Hein, Alexander, et al. "Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status." European journal of cancer (Oxford, England : 1990) vol. 155 (2021): 1-12. doi: https://doi.org/10.1016/j.ejca.2021.06.033
Hein A, Hartkopf AD, Emons J, Lux MP, Volz B, Taran FA, Overkamp F, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wurmthaler LA, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Kurbacher CM, Wuerstlein R, Thomssen C, Untch M, Fasching PA, Janni W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Kolberg HC. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. Eur J Cancer. 2021 Sep;155:1-12. doi: 10.1016/j.ejca.2021.06.033. Epub 2021 Jul 23. PMID: 34311211.
Copy Download .nbib Format: NLM
Fulminant COVID-19-Associated Myocarditis in an Otherwise Healthy Female.

Cureus

Milla-Godoy GC, Park R, Jiang W, Hartkopf MW, Treadwell T.
PMID: 33614338
Cureus. 2021 Jan 16;13(1):e12736. doi: 10.7759/cureus.12736.

An outbreak of a severe respiratory illness caused by a novel coronavirus that began in China in late 2019 has become a pandemic. We report the case of COVID-19-associated myocarditis in a 45-year-old healthy female who presented with solely...

Cite
Milla-Godoy GC, Park R, Jiang W, et al. Fulminant COVID-19-Associated Myocarditis in an Otherwise Healthy Female. Cureus. 2021;13(1):e12736doi: 10.7759/cureus.12736.
Milla-Godoy, G. C., Park, R., Jiang, W., Hartkopf, M. W., & Treadwell, T. (2021). Fulminant COVID-19-Associated Myocarditis in an Otherwise Healthy Female. Cureus, 13(1), e12736. https://doi.org/10.7759/cureus.12736
Milla-Godoy, Gabriela C, et al. "Fulminant COVID-19-Associated Myocarditis in an Otherwise Healthy Female." Cureus vol. 13,1 (2021): e12736. doi: https://doi.org/10.7759/cureus.12736
Milla-Godoy GC, Park R, Jiang W, Hartkopf MW, Treadwell T. Fulminant COVID-19-Associated Myocarditis in an Otherwise Healthy Female. Cureus. 2021 Jan 16;13(1):e12736. doi: 10.7759/cureus.12736. PMID: 33614338; PMCID: PMC7883749.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 75 entries